## Abstract ## Background This pilot study evaluated if acupuncture can alleviate radiationβinduced xerostomia among patients with cancer. Secondary objectives were to assess the effects of acupuncture on salivary flow and quality of life (QOL). ## Methods Nineteen patients received acupuncture
Acupuncture for xerostomia : Clinical update
β Scribed by Peter A. S. Johnstone; Richard C. Niemtzow; Robert H. Riffenburgh
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 98 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BACKGROUND
In the authors' clinic, patients with xerostomia after radiation therapy for malignancy have been offered acupuncture as potential palliation of their symptoms since November 1999. Preliminary data revealed that many patients achieve relief, even for symptoms refractory to pilocarpine therapy.
METHODS
Acupuncture technique has been refined since the authors' previous publication. Originally described as a twoβstep process, a single treatment with eight needles is now used. Three points are treated in each ear, and one in the radial aspect of each index finger. Patients are also provided a sugarβfree lozenge in the mouth to further stimulate salivation. Response is measured by the xerostomia inventory (XI).
RESULTS
Fifty patients have undergone 318 treatments (median, 5; range, 2β15 treatments). Median followβup since the first treatment is 224 days (range, 9β455 days). Median palliation as described by the XI was 9 points (range, 0β25 points). Response (defined as improvement of 10% or better over baseline XI values) occurred in 35 patients (70%). Twentyβfour patients (48%) have received benefit of 10 points or greater on the XI. Duration of effect for 13 patients (26%) has exceeded 3 months.
CONCLUSIONS
Acupuncture palliates xerostomia for many patients. A regimen of three to four weekly treatments followed by monthly sessions is now recommended, although some patients achieve lasting response without further therapy. Cancer 2002;94:1151β6. Β© 2002 American Cancer Society.
DOI 10.1002/cncr.10348
π SIMILAR VOLUMES
## Abstract Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Fo